Olympics spawned API shortages

Like some drugs, the Beijing Olympics has had adverse side effects. As you know, China shut down an entire swath of industry to clear the air over Beijing for the games. Among the shutdowns were plants that churn out raw materials for drugs and active pharmaceutical ingredients. During the games, Indian drugmakers were finding active ingredients scarce, and costly, too. And now South African pharma companies are complaining of Olympics-based raw materials shortages.

The problem is particularly acute in South Africa, which sets fixed prices for drugs. Though some ingredients have tripled in cost, local drugmakers have had to take the hit. And according to one pharma exec, the Olympics problem has been exacerbated by rising fuel prices and an increase in costs for commodities such as starch that are used in making many drugs. Some small drugmakers have even discontinued certain products because of ingredient shortages and rising prices, putting meds such as antidepressants, diuretics, penicillin, and brochodilators in short supply.

- read the Business Day article
- here's more on South Africa's problems

Suggested Articles

Just one week after inking a COVID-19 vaccine deal with the U.S. for 100 million doses, J&J reached a supply agreement twice that size with the EU.

Ahead of a critical flu season, AstraZeneca is upping its manufacturing efforts to deliver more FluMist doses than previously anticipated.

FDA handed NS Pharma’s Viltepso a speedy FDA nod based on the same dystrophin production data that supported two Sarepta drugs' approvals.